LCB

LegoChem Biosciences is a clinical-stage biopharmaceutical company headquartered in South Korea, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company utilizes its proprietary ConjuAll platform technology, which features site-specific conjugation and stable linker chemistry designed to enhance the therapeutic index and safety profile of ADC candidates. LegoChem has established a robust pipeline of oncology assets, including high-profile programs targeting HER2, Trop2, and ROR1, many of which are being developed through global partnerships with major pharmaceutical firms. In addition to its ADC focus, the company leverages its medicinal chemistry expertise to develop small molecule therapeutics for infectious diseases and fibrosis. LegoChem's business model emphasizes early-stage discovery and platform licensing, evidenced by multi-billion dollar deals with partners such as Janssen and Amgen.